These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 36310329)

  • 21. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination.
    Chua GT; Kwan MYW; Chui CSL; Smith RD; Cheung ECL; Ma T; Leung MTY; Tsao SSL; Kan E; Ng WKC; Chan VCM; Tai SM; Yu TC; Lee KP; Wong JSC; Lin YK; Shek CC; Leung ASY; Chow CK; Li KW; Ma J; Fung WY; Lee D; Ng MY; Wong WHS; Tsang HW; Kwok J; Leung D; Chung KL; Chow CB; Chan GCF; Leung WH; To KKW; Yuen KY; Lau YL; Wong ICK; Ip P
    Clin Infect Dis; 2022 Sep; 75(4):673-681. PubMed ID: 34849657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 vaccine effectiveness in children by age groups. A population-based study in Galicia, Spain.
    Mallah N; Pardo-Seco J; Ares-Gómez S; López-Pérez LR; González-Pérez JM; Rosón B; Otero-Barrós MT; Durán-Parrondo C; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro-Sánchez C; Rivero-Calle I; Gómez-Carballa A; Salas A; Martinón-Torres F
    Pediatr Allergy Immunol; 2023 Oct; 34(10):e14037. PubMed ID: 37877845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting.
    Yap J; Tham MY; Poh J; Toh D; Chan CL; Lim TW; Lim SL; Chia YW; Lim YT; Choo J; Ding ZP; Foo LL; Kuo S; Lau YH; Lee A; Yeo KK
    Ann Acad Med Singap; 2022 Feb; 51(2):96-100. PubMed ID: 35224605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Observed versus expected rates of myocarditis after SARS-CoV-2 vaccination: a population-based cohort study.
    Naveed Z; Li J; Spencer M; Wilton J; Naus M; García HAV; Otterstatter M; Janjua NZ
    CMAJ; 2022 Nov; 194(45):E1529-E1536. PubMed ID: 36410749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Systematic Review and Meta-analysis of the Association Between SARS-CoV-2 Vaccination and Myocarditis or Pericarditis.
    Gao J; Feng L; Li Y; Lowe S; Guo Z; Bentley R; Xie C; Wu B; Xie P; Xia W; Ma S; Liu H; Guo X; Uy JPN; Zhou Q; Wazir H; Sun C
    Am J Prev Med; 2023 Feb; 64(2):275-284. PubMed ID: 36266115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada.
    Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE
    JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature.
    Lane S; Yeomans A; Shakir S
    BMJ Open; 2022 May; 12(5):e059223. PubMed ID: 35613761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mRNA Vaccines against SARS-CoV-2: Advantages and Caveats.
    Echaide M; Chocarro de Erauso L; Bocanegra A; Blanco E; Kochan G; Escors D
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine.
    Kuan AS; Chen SP; Wang YF; Wang SJ
    Cephalalgia; 2023 Oct; 43(10):3331024231208110. PubMed ID: 37851648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021.
    Oster ME; Shay DK; Su JR; Gee J; Creech CB; Broder KR; Edwards K; Soslow JH; Dendy JM; Schlaudecker E; Lang SM; Barnett ED; Ruberg FL; Smith MJ; Campbell MJ; Lopes RD; Sperling LS; Baumblatt JA; Thompson DL; Marquez PL; Strid P; Woo J; Pugsley R; Reagan-Steiner S; DeStefano F; Shimabukuro TT
    JAMA; 2022 Jan; 327(4):331-340. PubMed ID: 35076665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis in adolescents and young adults: a Nordic cohort study.
    Hviid A; Nieminen TA; Pihlström N; Gunnes N; Dahl J; Karlstad Ø; Gulseth HL; Sundström A; Husby A; Hansen JV; Ljung R; Hovi P
    Eur Heart J; 2024 Apr; 45(15):1327-1335. PubMed ID: 38365960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.
    Pareek M; Sessa P; Polverino P; Sessa F; Kragholm KH; Sessa M
    Front Cardiovasc Med; 2023; 10():1210007. PubMed ID: 38075965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
    Chen C; Fu F; Ding L; Fang J; Xiao J
    Front Immunol; 2022; 13():938322. PubMed ID: 36172346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines.
    Milevoj Kopcinovic L; Unic A; Nikolac Gabaj N; Miler M; Vrtaric A; Bozovic M; Stefanovic M
    Lab Med; 2024 Mar; 55(2):162-168. PubMed ID: 37294928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network.
    Neuhann JM; Stemler J; Carcas A; Frías-Iniesta J; Bethe U; Heringer S; Tischmann L; Zarrouk M; Cüppers A; König F; Posch M; Cornely OA
    Trials; 2022 Oct; 23(1):865. PubMed ID: 36209129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guillain-Barré syndrome temporally associated with COVID-19 vaccines in Victoria, Australia.
    Osowicki J; Morgan HJ; Harris A; Clothier HJ; Buttery JP; Kiers L; Crawford NW;
    Vaccine; 2022 Dec; 40(52):7579-7585. PubMed ID: 36357291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myocarditis and Pericarditis following COVID-19 Vaccination in Thailand.
    Mahasing C; Doungngern P; Jaipong R; Nonmuti P; Chimmanee J; Wongsawat J; Boonyasirinant T; Wanlapakorn C; Leelapatana P; Yingchoncharoen T; Ngarmukos T; Chokephaibulkit K; Srimahachota S
    Vaccines (Basel); 2023 Mar; 11(4):. PubMed ID: 37112661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pregnancy Status at the Time of Coronavirus Disease 2019 Vaccination and Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Magnus MC; Håberg SE; Carlsen EØ; Kwong JC; Buchan SA; Fell DB
    Clin Infect Dis; 2023 Jan; 76(1):57-65. PubMed ID: 36071540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
    Barda N; Dagan N; Ben-Shlomo Y; Kepten E; Waxman J; Ohana R; Hernán MA; Lipsitch M; Kohane I; Netzer D; Reis BY; Balicer RD
    N Engl J Med; 2021 Sep; 385(12):1078-1090. PubMed ID: 34432976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.